Characteristics of patients achieving objective response to SU5416
Diagnosis . | Age, y/sex . | FLT3-ITD/Asp835 . | Karyotype . | PS . | CR 1 duration, mo . | Induction regimen . | No. prior salvage regimens . | Response . | No. therapy cycles to response . | Survival, mo . | Eventfree survival, mo . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AML | 64/M | N/N | + 8 | 0 | N/A | DA | None | PR | 3 | >8 | 4 |
| Prior MDS | BM blasts reduced from 43% to 13% PB blasts normalized from 9% of 11.7 WBC | ||||||||||
| AML | 62/F | N/N | Diploid | 1 | 4 | CAT + LT | 1 | PR | 4 | 7 | 6.5 |
| Prior MDS | BM blasts reduced from 33% to 7% PB blasts normalized from 2% of 1.2 WBC | ||||||||||
| AML | 74/M | N/Mut | + 14 | 1 | 14 | DA | 4 | HI | 2 | 3.5 | 3 |
| Prior MDS | - 7 | BM blasts reduced from 38% to 3% with normal CBC PB blasts normalized from 70% of 19.1 WBC Baseline platelets < 50 × 109 persisted | |||||||||
| RAEBT | 77/F | N/N | - 5 | 1 | 36 (from initial diagnosis) | (Prior erythropoietin, GCSF) | None | PR | 1 | >16 | 11 |
| - 7 | BM blasts reduced from 28% to 8% Normal baseline CBC |
Diagnosis . | Age, y/sex . | FLT3-ITD/Asp835 . | Karyotype . | PS . | CR 1 duration, mo . | Induction regimen . | No. prior salvage regimens . | Response . | No. therapy cycles to response . | Survival, mo . | Eventfree survival, mo . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AML | 64/M | N/N | + 8 | 0 | N/A | DA | None | PR | 3 | >8 | 4 |
| Prior MDS | BM blasts reduced from 43% to 13% PB blasts normalized from 9% of 11.7 WBC | ||||||||||
| AML | 62/F | N/N | Diploid | 1 | 4 | CAT + LT | 1 | PR | 4 | 7 | 6.5 |
| Prior MDS | BM blasts reduced from 33% to 7% PB blasts normalized from 2% of 1.2 WBC | ||||||||||
| AML | 74/M | N/Mut | + 14 | 1 | 14 | DA | 4 | HI | 2 | 3.5 | 3 |
| Prior MDS | - 7 | BM blasts reduced from 38% to 3% with normal CBC PB blasts normalized from 70% of 19.1 WBC Baseline platelets < 50 × 109 persisted | |||||||||
| RAEBT | 77/F | N/N | - 5 | 1 | 36 (from initial diagnosis) | (Prior erythropoietin, GCSF) | None | PR | 1 | >16 | 11 |
| - 7 | BM blasts reduced from 28% to 8% Normal baseline CBC |
PS indicates Eastern Cooperative Oncology Group (ECOG) performance score; N, normal Flt3; N/A, not applicable; D, daunorubicin; A, ara-C; BM, bone marrow; PB, peripheral blood; WBC, white cell count; T, topotecan; C, cyclophosphamide; LT, liposomal tretinoin; CBC, complete blood count; and Mut, Flt3 mutation at Asp835